January 24, 2014 3:21 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of
Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following
Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.The analyst reported that this news is “incrementally positive” for
Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.